There are not as many outcomes for patients with AD as there are with Psoriasis, for example, how else does OM1 define patients with deep clinical data?

Advanced treatments, including biologics, have been a mainstay of treatment for moderate-to-severe disease in PsO longer than AD and disease outcomes like a minimum %BSA serve in PsO as a threshold for initiating those therapies. There are fewer reported outcomes for AD as a condition and as a result it was determined to include all patients receiving potential therapies for moderate-to-severe AD (i.e., non-steroidal systemics).